Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TJX COMPANIES INC /DE/TJX · Entity 2870 | Director | June 09, 2026 | June 11, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, CO & FO | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TJX COMPANIES INC /DE/
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,126.12 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 636.87 · Balance 3,126.12 F1: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,152.62 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 26.5 · Balance 3,152.62 F2: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,126.12 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Grant · Acquired 636.87 · Balance 3,126.12 F3: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,152.62 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Grant · Acquired 26.5 · Balance 3,152.62 F4: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan.
F2: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan.
F3: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan.
F4: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,042 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 1,744 · Balance 47,042 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 26.5 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267657 · ownership.xml · derivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,152.62 Underlying: Common Stock · 26.5 shares Expires not disclosed F4 · derivative.exercise_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. F4 · derivative.expiration_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 636.87 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267657 · ownership.xml · derivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,126.12 Underlying: Common Stock · 636.87 shares Expires not disclosed F3 · derivative.exercise_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. F3 · derivative.expiration_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 26.5 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267657 · ownership.xml · derivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,152.62 Underlying: Common Stock · 26.5 shares Expires not disclosed F2 · derivative.exercise_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. F2 · derivative.expiration_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 636.87 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267657 · ownership.xml · derivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,126.12 Underlying: Common Stock · 636.87 shares Expires not disclosed F1 · derivative.exercise_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. F1 · derivative.expiration_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,744 | $485.11 | $846,031.84 |
DisclosureSEC source: 0000875320-26-000122 · wk-form4_1772150196.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,042 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,294 | $483.75 | $1,109,722.50 |
DisclosureSEC source: 0000875320-26-000100 · wk-form4_1771536607.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,786 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,365 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000100 · wk-form4_1771536607.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,080 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,565 | $487.76 | $2,226,624.40 |
DisclosureSEC source: 0000875320-26-000078 · wk-form4_1771451250.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,715 Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,045 | $468.41 | $1,426,308.45 |
DisclosureSEC source: 0000875320-26-000054 · wk-form4_1770934225.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,280 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000028 · wk-form4_1769463497.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,325 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000028 · wk-form4_1769463497.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,165 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,532 | $0.00 Strike: $189.38 | $0.00 |
DisclosureSEC source: 0000875320-26-000002 · wk-form4_1767906275.xml · derivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,532 shares Expires 2029-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,532 | $461.00 | $4,394,252.00 |
DisclosureSEC source: 0000875320-26-000002 · wk-form4_1767906275.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,725 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/09/2025. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 9,532 | $189.38 | $1,805,170.16 |
DisclosureSEC source: 0000875320-26-000002 · wk-form4_1767906275.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $461.00 | $3,227,000.00 |
DisclosureSEC source: 0000875320-25-000247 · wk-form4_1764969405.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,725 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/9/2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $451.00 | $3,157,000.00 |
DisclosureSEC source: 0000875320-25-000247 · wk-form4_1764969405.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,725 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/9/2025. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:00 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 20.6 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085537 · ownership.xml · derivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,489.25 Underlying: Common Stock · 20.6 shares Expires not disclosed F4 · derivative.exercise_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 4, 2024. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. F4 · derivative.expiration_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 4, 2024. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:00 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 793.4 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085537 · ownership.xml · derivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,468.65 Underlying: Common Stock · 793.4 shares Expires not disclosed F3 · derivative.exercise_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $100,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. F3 · derivative.expiration_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $100,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:00 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 20.6 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085537 · ownership.xml · derivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,489.25 Underlying: Common Stock · 20.6 shares Expires not disclosed F2 · derivative.exercise_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 4, 2024. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. F2 · derivative.expiration_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 4, 2024. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:00 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 793.4 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085537 · ownership.xml · derivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,468.65 Underlying: Common Stock · 793.4 shares Expires not disclosed F1 · derivative.exercise_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $100,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. F1 · derivative.expiration_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $100,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,298 | $500.00 | $1,649,000.00 |
DisclosureSEC source: 0000875320-25-000148 · wk-form4_1741810299.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,671 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,962 | $479.61 | $2,379,824.82 |
DisclosureSEC source: 0000875320-25-000137 · wk-form4_1740779526.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,969 Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,310 | $483.28 | $1,599,656.80 |
DisclosureSEC source: 0000875320-25-000117 · wk-form4_1740604600.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,931 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,293 | $463.46 | $1,062,713.78 |
DisclosureSEC source: 0000875320-25-000097 · wk-form4_1740001110.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,241 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000075 · wk-form4_1739568057.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,534 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,649 | $467.98 | $1,239,679.02 |
DisclosureSEC source: 0000875320-25-000050 · wk-form4_1739397137.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,879 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000026 · wk-form4_1738878299.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,528 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000026 · wk-form4_1738878299.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,414 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,000 | $518.27 | $1,554,810.00 |
DisclosureSEC source: 0000875320-24-000227 · wk-form4_1731532506.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,137 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:58 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 9.35 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070021 · ownership.xml · derivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675.25 Underlying: Common Stock · 9.35 shares Expires not disclosed F4 · derivative.exercise_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 6, 2023. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. F4 · derivative.expiration_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 6, 2023. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:58 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 944.55 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070021 · ownership.xml · derivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,665.9 Underlying: Common Stock · 944.55 shares Expires not disclosed F3 · derivative.exercise_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a value of $100,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. F3 · derivative.expiration_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a value of $100,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:58 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 9.35 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070021 · ownership.xml · derivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675.25 Underlying: Common Stock · 9.35 shares Expires not disclosed F2 · derivative.exercise_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 6, 2023. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. F2 · derivative.expiration_date: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 6, 2023. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:58 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 944.55 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070021 · ownership.xml · derivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,665.9 Underlying: Common Stock · 944.55 shares Expires not disclosed F1 · derivative.exercise_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a value of $100,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. F1 · derivative.expiration_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a value of $100,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,250 | $460.00 | $1,495,000.00 |
DisclosureSEC source: 0000875320-24-000170 · wk-form4_1717618308.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,137 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 02/26/2024. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,250 | $454.79 | $1,478,067.50 |
DisclosureSEC source: 0000875320-24-000162 · wk-form4_1717099663.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,387 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 02/26/2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,309 | $431.79 | $1,428,793.11 |
DisclosureSEC source: 0000875320-24-000111 · wk-form4_1709071690.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,583 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,812 | $420.58 | $1,182,670.96 |
DisclosureSEC source: 0000875320-24-000082 · wk-form4_1708552098.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,892 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,750 | $424.01 | $1,590,037.50 |
DisclosureSEC source: 0000875320-24-000082 · wk-form4_1708552098.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,704 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,607 | $422.74 | $1,102,083.18 |
DisclosureSEC source: 0000875320-24-000057 · wk-form4_1707863641.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,454 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000034 · wk-form4_1707428861.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,061 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000034 · wk-form4_1707428861.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,947 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000034 · wk-form4_1707428861.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,507 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,000 | $405.00 | $1,215,000.00 |
DisclosureSEC source: 0000875320-24-000002 · wk-form4_1704403018.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,693 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/18/2023. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,000 | $349.88 | $1,049,640.00 |
DisclosureSEC source: 0000875320-23-000043 · wk-form4_1700600822.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,693 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/18/2023. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $349.88 (range $349.76 to $350.00). Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 21:00 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 721.35 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050394 · doc4.xml · derivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721.35 Underlying: Common Stock · 721.35 shares Expires not disclosed F2 · derivative.exercise_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a value of $92,500, prorated for the number of days between the Director's election to the Board and the expected date of the next annual meeting of stockholders. Shares vest on the date immediately preceding the date of the Company's annual meeting of stockholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. F2 · derivative.expiration_date: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a value of $92,500, prorated for the number of days between the Director's election to the Board and the expected date of the next annual meeting of stockholders. Shares vest on the date immediately preceding the date of the Company's annual meeting of stockholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 21:00 UTC | TJX COMPANIES INC /DE/ TJX · Entity 2870 | GrantDeferred Stock Units · Derivative | 721.35 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050394 · doc4.xml · derivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721.35 Underlying: Common Stock · 721.35 shares Expires not disclosed F1 · derivative.exercise_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a value of $92,500, prorated for the number of days between the Director's election to the Board and the expected date of the next annual meeting of stockholders. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. F1 · derivative.expiration_date: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a value of $92,500, prorated for the number of days between the Director's election to the Board and the expected date of the next annual meeting of stockholders. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,768 | $305.38 | $539,911.84 |
DisclosureSEC source: 0001209191-23-021394 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,611 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2022. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 16 | $301.13 | $4,818.08 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 6 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,379 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $299.58 | $71,899.20 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,395 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $299.58 (range $299.09 to $300.06). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 360 | $298.09 | $107,312.40 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,635 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $298.09 (range $297.65 to $298.48). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.